What Selank is
Selank is a synthetic heptapeptide with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro. It was developed and studied primarily in Russia for anxiety-related conditions. FDA’s substance database records the chemical identity but explicitly warns that a UNII identifier does not imply regulatory review or approval.[1]
No Selank product is FDA-approved in the United States. Foreign use and a chemical identifier do not validate a U.S. compounded nasal spray, injectable vial, or online research product.
Human evidence consists of small regional studies
A Russian comparative study enrolled 62 patients with generalized anxiety disorder or neurasthenia and compared Selank in 30 participants with medazepam in 32, reporting similar anxiolytic effects.[2] Another Russian comparative study enrolled 60 patients with phobic-anxiety or somatoform disorders and reported benefit relative to phenazepam.[3]
These reports provide a human signal, but their small size, limited accessible methods, active comparators rather than a clearly described placebo framework, regional publication, and lack of independent large replication prevent a reliable estimate of efficacy. They do not establish cognitive enhancement, stress resilience, depression treatment, neuroprotection, or benefit in healthy people.
Mechanistic claims remain preliminary
Studies have explored enkephalin metabolism, immune markers, neurotransmitter systems, and gene expression. These biomarker and preclinical findings may generate hypotheses but do not substitute for replicated patient-centered outcomes. A change in an enzyme, cytokine, or animal behavior is not proof of clinical anxiolysis or nootropic benefit.
Safety and product-quality uncertainty
The small human reports cannot characterize uncommon events, interactions, withdrawal effects, pregnancy risk, or long-term safety. FDA’s current compounding-risk page says Selank acetate may pose immunogenicity risk from aggregation and peptide-related impurities and that FDA lacks important human safety information.[4]
The regulatory history of the nomination is nuanced: a prior category-2 entry was removed after the nominator clarified that it had intended to nominate a different bulk substance, not because FDA established Selank as safe or effective.[5] Compounded drugs remain unapproved and are not premarket-verified for safety, effectiveness, or quality.[6]
Evidence conclusion
Selank receives grade C: small human studies suggest possible anxiolytic activity, but the evidence is not independently replicated or sufficient for a dependable clinical conclusion. No U.S. approval, established dose, long-term safety profile, or validated cognitive-enhancement use exists. Teloryx withholds nasal, injectable, stacking, and cycle instructions.